Induced pluripotent stem cell (iPSC)-derived NK cells are revolutionising cancer immunotherapy by offering a scalable and reliable source of immune cells for therapeutic use. These NK cells are engineered to target and eliminate a wider range of tumours, providing new opportunities for treatment.

Unlike traditional donor-derived NK cells, iPSC-derived NK cells offer a limitless and consistent supply, enabling genetic modifications to enhance their therapeutic potential. With the integration of CAR technology and other innovations, these cells represent a promising frontier in personalised medicine.

As research progresses, iPSC-derived NK cells are poised to play an increasingly important role in the future of medicine and the treatment of various cancers, inflammatory diseases, and even neurological disorders – enabling precision treatments with fewer limitations.

Cartherics’ CEO, Prof. Alan Trounson and Scientific Advisor, Dr. Richard Boyd, recently prepared an article for BioInformant exploring the latest advancements and the exciting future of NK cell-based treatments. Read it here: https://bioinformant.com/ipsc-derived-nk-cells/